News

Published on 14 Nov 2023 on Zacks via Yahoo Finance

Can IDEAYA Biosciences, Inc. (IDYA) Climb 25.48% to Reach the Level Wall Street Analysts Expect?


Article preview image

Shares of IDEAYA Biosciences, Inc. (IDYA) have gained 18.8% over the past four weeks to close the last trading session at $29.20, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $36.64 indicates a potential upside of 25.5%.

The mean estimate comprises 11 short-term price targets with a standard deviation of $4.90. While the lowest estimate of $26 indicates a 11% decline from the current price level, the most optimistic analyst expects the stock to surge 50.7% to reach $44. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.

While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice.

NASDAQ.IDYA price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Here’s Why IDEAYA Biosciences, Inc. (IDYA) Will Double in 2025

We recently compiled a list of the 12 Stocks That Will Double in 2025. In this article, we are go...

Insider Monkey · via Yahoo Finance 3 Feb 2025

Ideaya Biosciences Inc. (IDYA): Among the NASDAQ Stocks with Biggest Upside...

We recently compiled a list of the 12 NASDAQ Stocks with Biggest Upside Potential According to...

Insider Monkey · via Yahoo Finance 22 Nov 2024

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Analysts Are Pretty Bullish On The Stock After Recent Results

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) shareholders are probably feeling a little disappointed, s...

Simply Wall St. via Yahoo Finance 23 Feb 2024

IDEAYA Biosciences Inc CEO Yujiro Hata Sells 99,372 Shares

On February 9, 2024, Yujiro Hata, the President and CEO of IDEAYA Biosciences Inc (NASDAQ:IDYA), ...

GuruFocus.com via Yahoo Finance 13 Feb 2024

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is largely controlled by institutional shareholders who own...

Key Insights Institutions' substantial holdings in IDEAYA Biosciences implies that they have sign...

Simply Wall St. via Yahoo Finance 28 Jan 2024

IDEAYA Biosciences Inc President and CEO Yujiro Hata Sells 75,000 Shares

On January 16, 2024, President and CEO Yujiro Hata sold 75,000 shares of IDEAYA Biosciences Inc (...

GuruFocus.com via Yahoo Finance 21 Jan 2024

IDEAYA Biosciences, Inc. (IDYA) Moves 7.6% Higher: Will This Strength Last?

IDEAYA Biosciences, Inc. (IDYA) shares soared 7.6% in the last trading session to close at $39.74...

Zacks via Yahoo Finance 14 Jan 2024

Can IDEAYA Biosciences, Inc. (IDYA) Climb 25.48% to Reach the Level Wall Street Analysts Expect?

Shares of IDEAYA Biosciences, Inc. (IDYA) have gained 18.8% over the past four weeks to close the...

Zacks via Yahoo Finance 14 Nov 2023

Analysts' Revenue Estimates For IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Are Surging Higher

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) shareholders will have a reason to smile today, with the a...

Simply Wall St. via Yahoo Finance 9 Nov 2023

IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Lags Revenue Estimates

IDEAYA Biosciences, Inc. (IDYA) came out with a quarterly loss of $0.46 per share versus the Zack...

Zacks via Yahoo Finance 7 Nov 2023